The acontractile bladder (AcB) is a urodynamic-based diagnosis wherein the bladder is unable to demonstrate any contraction during a pressure flow study. Although it is often grouped with underactive bladder, it is a unique phenomenon and should be investigated independently. The purpose of the present review was to examine the current literature on AcB regarding its pathology, diagnosis, current management guidelines, and future developments. We performed a review of the PubMed database, classifying the evidence for AcB pathology, diagnosis, treatment, and potential future treatments. Over the 67 years covered in our review period, 42 studies were identified that met our criteria. Studies were largely poor quality and mainly consisted of retrospective review or animal models. The underlying pathology of AcB is variable with both neurological and myogenic aetiologies. Treatment is largely tailored for renal preservation and reduction of infection. Although future developments may allow more functional restorative treatments, current treatments mainly focus on bladder drainage. AcB is a unique and understudied bladder phenomenon. Treatment is largely based on symptoms and presentation. While cellular therapy and neuromodulation may hold promise, further research is needed into the underlying neuro-urological pathophysiology of this disease so that we may better develop future treatments.
Introduction
According to ICS definition from 2002: 'Acontractile detrusor is one that cannot be demonstrated to contract during urodynamic studies' [1] . This definition was revised 2010 to: 'the detrusor cannot contract during urodynamic studies resulting in prolonged bladder emptying within a normal time span ' [2] . This finding is a separate finding from detrusor underactivity (DU): 'detrusor contraction of reduced strength and/or duration, resulting in prolonged bladder emptying and/or a failure to achieve complete bladder emptying within a normal time span'. Whilst presentations are similar, evidence suggests that these are two distinct entities rather than a single, progressive spectrum [3] . Regardless, these urodynamic diagnoses are generally grouped together under the clinical diagnosis of 'underactive bladder' (UAB).
Acontractile detrusor occurs in~5-17% of patients with LUTS. While the presentation may be uniform, the underlying aetiology of acontractile detrusor may be due a wide range of metabolic, infectious, autoimmune, congenital, and degenerative changes that affect the myogenic or neurogenic properties of the bladder. Acontractile detrusor may also be the result of paruresis: the inability to initiate a contraction whilst being observed. As such psychosocial stressors may distract from the true underlying presentation and underlying pathology. Differentiation between aetiologies thus requires an understanding of the nuances of this presentation including differences in symptoms, patient history, and physical data to formulate the correct diagnosis. Furthermore, although treatment options are currently limited, new developments will potentially allow us to treat the different categories with pathology specific solutions in the near future.
The purpose of the present review was to examine the current literature regarding acontractile detrusor and its pathology, diagnosis, current management guidelines, and possible future developments. This was to discover if the acontractile detrusor, as demonstrated by conventional urodynamic study (UDS), can be separated from DU. Furthermore, we examine that from a pathophysiological point of view an acontractile detrusor is only one potential cause of an acontractile bladder (AcB), as the lack of detrusor contraction during urodynamic studies may not be caused by the myogenic failure of detrusor muscle to contract. We thus suggest that the term acontractile detrusor is replaced by acontractile bladder, covering urodynamic diagnosis, symptoms, and underlying pathophysiology. This is important, particularly within the ageing population, where this is likely to be an increasingly prevalent clinical problem.
Evidence Acquisition
The PubMed database was searched for all English manuscripts pertaining to AcB from 1 January 1950 to 1 January 2017. We used the search terms 'acontractile bladder', 'acontractile detrusor', 'hypocontractile bladder', 'hypocontractile detrusor', and 'detrusor areflexia'. Additional studies referenced in the resultant studies were also considered for review. Abstracts were then screened for relevance to AcB. The full texts of the selected studies were then assessed for their content pertaining to pathophysiology, diagnostic methods, management, and bench research with potential for future applications. Original studies, review articles, commentaries, and editorials were all included in this review.
Evidence Synthesis
The initial search generated 423 studies for consideration. In addition, key reference standards such as ICS terminology and proceedings were reviewed. Papers were selected based on their discussion of relevant topics including bladder contractility, bladder emptying, denervation, overdistension, retention, UDS findings of hypocontractility or acontractile detrusor. Independent review was done by the two senior authors for the final selection. After elimination of duplicates between search terms and reviewing studies for content, a total of 42 studies were included in this review. An additional three studies were added on peer review.
Pathophysiology
Although the presentation of AcB is significantly different DU many of the pathological mechanisms are similar. This has led to the debate as to whether AcB is a distinct entity, or merely an extreme case of DU [4] . Data suggest that patients with DU do not progress to acontractility and as such this is separate condition with similar mechanisms [5] .
Neurogenic AcB
The terms 'neurogenic bladder' and 'areflexia' have sometimes been used synonymously with acontractile detrusor. However, 'neurogenic bladder' includes a wide range of urological dysfunctions and the ICI document from 2010 [2] states: 'the term "areflexia" has been used when there is a neurological cause, but should be replaced by "neurogenic acontractile detrusor"'. Micturition is controlled by a complex spino-bulbospinal pathway that incorporates excitatory and inhibitory features from the CNS and peripheral nervous system. As such neurogenic AcB can result from a defect at many different points throughout the system, each with a slightly different presentation [6] . The upper motor neurones of the efferent pathway travel within the anterior horn of the spinal cord before synapsing with the lower motors neurones that travel to the musculature. While the most common causes of injury to anterior horn are trauma or iatrogenic, several other acute and chronic diseases such as polio, amyotrophic lateral sclerosis, and progressive muscular atrophy also damage the anterior horn. Patients with polio, for example, have a reported rate of lower urinary tract dysfunction of 4-42% and generally present retention, intact sensation, and AcB [7] .
Converse to the efferent nervous system in the anterior horn, the posterior horn carries the afferent input for sensation of the bladder. While these changes do not impact contractility directly, they can lead to AcB through high pressure overdistention injury due to lack of sensation. Distention in turn leads ischaemia and oxidative stress, with subsequent myogenic changes as described below [8] . The most common causes of such afferent pathway injuries include diabetic neuropathy and pernicious anaemia. Table 1 lists the common causes of neuronal damage leading to AcB and their locations within the nervous system [9] . For cases where the injury site is in question, UDS findings can often be helpful, as loss of compliance is more characteristic of anterior horn than posterior horn injuries.
Suprasacral spinal injuries may also cause flaccid muscle paralysis in a condition known as spinal shock but this condition should be kept separate from AcB because here the areflexia is temporary. In these patients, some electromyographic activity may be recorded from the striated sphincter, the normal guarding reflex (striated sphincter response during filling and to rapid increases in intra-abdominal pressure) is absent and there is no voluntary control. While the duration of acontractility is highly variable, the average length of time before progressing to spasticity is 6-12 weeks [10] .
Myogenic AcB
Myogenic AcB refers to the condition where the inability to contract originates from within the detrusor muscle (detrusor muscle layer) itself rather than nerve signalling. The primary pathophysiological mechanism is thought to be an increased deposition of fibrous tissue and collagen between the muscle bundles, rather than reduction of myocyte contractility [11] . This leads to reduced excitability and loss of detrusor muscle contractility and the spontaneous micro-contractions Beyond changes to the superstructure of the detrusor muscle layer, damage to bladder smooth muscle myocytes can also induce myogenic AcB. Elbadawi et al. [14] described ultrastructural changes and dysfunction of cellular mechanisms including ion storage/exchange, excitationcontraction coupling, calcium storage, decreased transmission of potential energy across myocytes, alterations in intercellular connections and excitability, intracellular signalling, receptor density and distribution, as additional factors for the poorly contracting detrusor. It is difficult to assess the functional importance of all these changes, many of which seem to be consequences of other pathophysiologically more important factors ('major players'), such as ischaemia, normal ageing, damage of bladder peripheral afferent-efferent pathways, or spinal micturition center injury. Most often myogenic changes are related to ischaemia secondary to overdistention caused by BOO or diabetic cystopathy. Lack of contractile stimulus (acetylcholine and ATP) can also lead to subsequent loss of muscle tissue [16] .
Diagnosis
AcB is a urodynamic entity and requires pressure-flow studies (PFS) for a formal diagnosis. It is not clinically relevant in the absence of symptoms or urinary retention. Differentiation of DU and the AcB is not possible without PFS. In both cases patients can present with a constellation of symptoms known as UAB: 'characterised by a slow urinary stream, hesitancy and straining to void, with or without a feeling of incomplete emptying and dribbling, often with storage symptoms'. UAB does not imply a urodynamic finding, and is instead a clinical diagnosis [3] . Diagnostic differentiation is important in that it can identify patients who could potentially benefit from certain treatments (and which treatments may be more effective for patient subsets) vs those for whom improvement is unlikely and passive drainage through catheterisation or diversion is a more fitting option.
Urodynamic Findings
The defining characteristic of AcB is complete absence of a detrusor pressure wave on PFS [1] (Fig. 1 ). It is important to differentiate this from patients who simply cannot initiate voiding during urodynamic testing. Thus, a diagnosis of AcB requires symptoms or incomplete bladder emptying, as well as persistence to be diagnosed. Patients may fail to generate a successful contraction in the clinical setting due to the phenomenon of paruresis, characterised by the inability to void in a social setting (including the urodynamics laboratory) [17] . This was demonstrated in a study by van Koeveringe et al. [18] , in which 84% of patients with AcB on a conventional UDS demonstrated some detrusor contractility on an ambulatory UDS at home. More recently, Rademakers et al. [19] found similar results in 239 patients investigated by ambulatory urodynamic monitoring due to LUTS, where a subgroup of 79 patients (33%) were suspected to have an AcB. However, 83.5% of these patients thought to have AcB on conventional UDS showed some degree of contraction on ambulatory studies. These findings suggest that for those patients where the diagnosis of AcB is in question, a simple PFS may not be enough, and the authors emphasised that ambulatory UDS are expected to gain a more prominent role in the diagnostic algorithm for DU and the differentiation of this entity from true bladder acontractility.
Beyond simply measuring the presence or absence of detrusor contraction, UDS provides other important information in the patient with AcB. For the patient's longterm health, the issue of most importance is bladder compliance and detrusor leak-point pressure. Whilst the traditionally used safe-unsafe threshold value for upper tract damage is 40 cmH 2 O, there is no absolute value that undoubtedly determines risk [20] . Likewise, although overdistention induced ischaemia is a primary cause of myogenic damage to the bladder; elevated post-voiding residual urine volume (PVR), and degree of poor bladder compliance have no defined 'safe' values. With regards to what constitutes an abnormal PVR, the most widely accepted volume is >300 mL, as indicative of chronic urinary retention. By contrast, others have suggested that a PVR of >40% of bladder capacity is abnormal but there remains a lack of consensus on this issue [9] . Another question relevant to clinical practice is: what is the 'safe' threshold for PVR. Patients with very large PVRs (e.g. >1 000 mL) but with minimal symptoms and normal renal function are not infrequently encountered in clinical practice.
Other Testing
In addition to conventional and ambulatory UDS, several other tests have been suggested to assess detrusor function. These tests have largely fallen out of favour due to their low sensitivity and specificity in the face of modern urodynamic testing, but may still be of some use in select patients. For those patients with neurogenic AcB where the location of the lesion is in question, fast-filling cystometry with cooled saline (the 'ice water test') is considered a discriminative test between an upper and lower motor neurone lesion. Patients with upper motor lesions will develop a detrusor contraction if the detrusor muscle is intact, whilst patients with lower lesions will not. The value of this test is questionable as various studies have put its success rate between 46% and 92% depending on the pathological condition [21] .
Another historical test that has largely fallen out of favour is the bethanechol test. Popular in the 1970s and 1980s, it was thought that a positive bethanechol test (detrusor contraction >25 cmH 2 O) provided proof of a detrusor denervation hypersensitivity and the muscular integrity of an acontractile detrusor [9] . Unfortunately, this test has shown high rates of false negatives and false positives, and as such is no longer appropriate for clinical use [22] . Riedl et al. [23] 
In patients with AcB and poor compliance there is great risk to the upper urinary tract from a raised bladder pressure. The speed of onset and severity of upper tract injury depends on the pattern of neuro-urological dysfunction (such as urinary sphincter function) and patient sex. In females, this situation often leads to urinary incontinence due to the fact that bladder wall-derived intravesical pressures exceed urethral opening and flow pressures before achieving sufficient magnitude to cause upper tract damage (although patientspecific factors such as body habitus, mobility, and positioning can potentially alter these parameters). This is contrasted to the situation in men, particularly those affected by spinal cord injury where progressive upper tract dilatation and deterioration in renal function is more common [24] .
Management
The management of AcB is dependent on LUTS, PVR, changes in the upper tract if any, and presence or absence of symptomatic UTI.
Physiotherapy and Behavioural Changes Including Pelvic Floor Retraining
Patients with dysfunctional or Valsalva-assisted voiding and AcB on UDS are best managed by pelvic floor retraining and behavioural modification, such as timed or prompted voiding. Valsalva voiding is unphysiological and can lead to increase in UTI in females, due to the stop-start voiding [25] . Females presenting with stress urinary incontinence and frequency, show AcB on UDS, dysfunctional voiding, and a PVR. This can improve with pelvic floor retraining as shown in children [26] .
Both children and adults with dysfunctional voiding have been treated with pelvic floor physiotherapy with biofeedback, with some success [27, 28] . In these patients, it is postulated that inadequate relaxation of the pelvic floor musculature and external urethral sphincter has inhibitory effect on the detrusor. van Koeveringe et al. [18] reported that 24% of patients with AcB on conventional UDS, but not on ambulatory UDS, were successfully treated with physiotherapy suggesting a potential role of physiotherapy in this group.
Intermittent Self-Catheterisation (ISC)
Where bladder drainage is indicated, ISC is preferable to an indwelling catheter due to lower rates of infection and less impact on quality of life. The patient should have sufficient cognitive function and have good dexterity. The timing of ISC depends on individual circumstances. There is no evidence to support one regimen over another. Bacteriuria is a frequent finding in patients performing ISC. In the absence of clinical signs of infection there is no evidence antimicrobial therapy is necessary.
Neuromodulation
Sacral neuromodulation was first described over three decades ago [29] . One of the clinical problems where it has found use is in patients with Fowler's syndrome. This rare condition is found in women, generally under the age of 30 years, and is defined by non-obstructive urinary retention [30, 31] . The pathophysiology underlying this problem is poorly understood, but the most accepted theory is that sphincteric or pelvic floor muscle contraction has a reflex inhibitory effect on the detrusor muscle by prevention of transmission of bladder afferent activity at the level of the sacral cord. This in turn leads to the urodynamic finding of poorly contractile or AcB without an obvious neurological abnormality. Sacral neuromodulation is thought to work through inhibition of urethral afferent signalling; allowing normal afferent flow from the bladder to the brain, with this there is a restoration of normal bladder sensation and bladder contraction. Success rates of neuromodulation for patients with AcB are significantly worse than those for patients with any degree of contractility. In a recent study Drossaerts et al. [32] demonstrated that patients with AcB on conventional and ambulatory UDS had successful treatment with sacral neuromodulation in only 35% and 17% of cases, respectively (as compared to 67% and 32% of patients with hypocontractility). These findings suggest that sacral neuromodulation is only successful in treating AcB for a select few patients. For those patients who do see success, it may be that they were underdiagnosed through the use of conventional UDS, and they may have some degree of contraction when measured with ambulatory UDS.
Bladder Stimulation
Several electrical nerve stimulation techniques have been applied with the aim of inducing bladder contraction in patients AcB. Giles Brindley [33] developed the anterior sacral root stimulator, intended for use in those with a complete spinal cord injury. The anterior sacral roots are stimulated via implantable stimulation wires, which are activated through the use an external transmitter activating the implanted receiver [33, 34] . The urethral somatic afferents are also simulated at the same time causing sphincter contraction. This problem is overcome to a degree by using intermittent stimulation, which permits voiding, as smooth muscle has a longer relaxation time than skeletal muscle. The overall effect of this is a sustained bladder contraction with short periods of sphincter contraction leading to an intermittent but effective void. A modification to the technique was later introduced comprising of sacral root rhizotomy to abolish reflex bladder activity [35] . This technique is very effective for the specific group of patients with complete spinal cord injury; however, it has fallen out of favour in most recent years due to the reluctance of patients to undergo ablative neural interventions.
Intravesical electrotherapy (IVE) was first described in the 1950s by Katona [36] . The bladder is stimulated by the application of current passed through a transurethral electrode after the bladder is filled with saline solution [15] . Stimulation is delivered as daily sessions of~1 h. A total of 10-15 sessions are given initially as a trial. Studies in small animals have shown that IVE works upon the myelinated Ad fibres, which leads to central reflexic activation of the detrusor [37] . It is hypothesised that through repetitive stimulation, the myelinated Ad fibres are upregulated, which leads to enhanced activity during both the storage and voiding phase, resulting in greater sensation and more efficient emptying. For IVE to be successful there is a need for intact innervation.
The vast majority of published reports of IVE have been in the paediatric group. Most of these studies consist of small case series, which are heterogeneous in terms of inclusion criteria, stimulation technique, and schedules. In a study by Primus et al. [38] in adults with mainly neurogenic AcB, 39% had a restoration of contractile activity after treatment. However, it should be noted that several studies have not shown any benefit to IVE, these studies include to hitherto the only sham-controlled randomised study [39] . A potentially confounding factor in the studies showing success is the intensive bladder training (AEbiofeedback) schedule that is undertaken alongside IVE [40] . The major drawback of this technique is the time and resource consuming nature of undertaking multiple treatments, which may explain the lack of uptake [41] .
Experimental Surgical Intervention
After initial case reports describing bladder muscle wrap using rectus femoris and rectus abdomini muscles, Stenzl et al. [42] reported the first series of bladder wrap procedures in 1998, using latissmus dorsi in patients with AcB. The procedure involves harvesting the lattimus dorsi muscle, anastomosing its vascular pedicle to the inferior epigastric vessels and coapting its nerve to the intercostal nerve. The muscle is the wrapped around the bladder and anchored to the pelvic floor. Gakis et al. [43] reported the long-term outcomes of these patients in 2011. All 24 patients with AcB were catheter dependent. In total, 17/24 patients regained the ability to void efficiently (mean PVR = 25 mL). The bladder contractility index increased significantly from a mean (SD) of 20.1 (7.6) to 176.2 (25.4) (P < 0.001). The main concern was the high rate of complications occurring in about one-third of patients. These included wound infections, pelvic collections and venous thromboembolism, albeit no long-term problems were reported.
Future Directions

Pharmacotherapy
There currently exists no effective pharmacological treatment for AcB. Several agents have been studied, in particular the parasympathomimetic, bethanechol. These studies have shown little evidence of benefit in addition to some potentially serious side-effects, such as cardiac depression [44] . Intravesical prostaglandin therapy has been studied in the postoperative setting in the prevention of urinary retention. There is evidence from a pooled analysis of three randomised trials demonstrating a statistically significant relationship between instillation and successful voiding in this context (risk ratio 3.07) [45] . The impact of these agents in patients with AcB is largely unknown.
There exist several potential pathways to achieve bladder contraction in patients with AcB, targeting different aspects of the micturition reflex. Broadly, potential agents work by increasing detrusor contractile force, afferent signalling, or reducing outlet resistance. Exogenous prostaglandins hold some promise, and uroselective agents with little effect on the gastrointestinal and genital tract are under investigation. The key challenge will be getting such agents to be effective when taken by the oral route. Transient receptor potential vanilloid channel agonists (e.g. TRPV4 agonist GSK1016790A) are molecules responsible to for converting thermal energy to neural signals and were shown experimentally to increase bladder contractility. A uroselective muscarinic agonist would be an interesting prospect that would allow the dosage to be increased without risk of systemic side-effects; however, this is unlikely to be realistic possibility in the near future. An important limitation is that all agents contracting the bladder without relaxing the outlet region would have the capacity to cause an increase in intravesical pressure with potential negative consequences. Further insights may be gained by studying similar problems of poor contractility in other systems, such as the gut, and how these are overcome with drugs such as prokinetics. Ultimately, if we are to develop effective pharmacotherapy for AcB it will be important to first gain a deeper understanding of the normal physiological mechanisms involved in voiding and how these are altered by pathophysiologies leading to AcB.
Stem Cell Therapy
Much has been published on tissue engineering for bladder substitution or augmented reconstruction in patients with both malignant and benign disease; however, a functional innervated tissue-engineered bladder remains a distant prospect [46] . An alternative approach is injection therapy using stem cells, which has shown promising results in preclinical studies. Stem cells were originally thought to act by differentiating into various cell types, thereby replacing damaged cells and restoring functional deficits. Even if such a mechanism cannot be excluded, the current belief is that a main action is exerted by the stem cells secreting bioactive factors that direct other stem cells to the target organ. In addition, stem cells may exert a number of other effects that can improve bladder dysfunction, as they may have antiapoptotic, anti-fibrotic, and immunomodulatory properties, and can induce neovascularisation [47] .
Several different stem cell sources have been investigated using animal models of AcB. In these cases the animals were induced into AcB (through techniques including bilateral iliac artery ligation, pelvic nerve injury, and diabetic bladder dysfunction), and subsequently underwent injection of stem cells either directly into the bladder or into the nerve supply. After a recovery period the animals' bladder function was tested using cystometry and PFS. Table 2 highlights these studies [48] [49] [50] [51] [52] [53] . In each case, the experimenters were able to increase bladder contractility through the injection and differentiation of stem cells. Although these treatments have not yet progressed to human subjects, they remain the most promising future therapy and highlight the need for understanding the pathophysiology and underlying target of AcB.
Conclusions
AcB is a unique and understudied bladder phenomenon. In contrast to DU it has a defined urodynamic endpoint. This endpoint can be established by using ambulatory UDS, which seems to be a valuable discriminating diagnostic tool. AcB should be viewed as its own clinical entity rather than a mere extension of UAB. Diagnostic differentiation is important in that it can identify patients who could potentially benefit 200 © 2018 The Authors BJU International © 2018 BJU International from certain treatments (and which treatments may be more effective for patient subsets) vs those for whom improvement is unlikely and passive drainage through catheterisation or diversion is a more fitting option. Treatment of AcB is largely based on symptoms and presentation, and further research is needed to better develop new treatments. Future studies, using extended urodynamic investigation to support the diagnosis, and e.g. bladder biopsy studies (histology and organ-bath investigations) to elucidate morphological and possible pathophysiological bladder changes, are needed.
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